JAB-3312 + osimertinib

JAB-3312 + osimertinib is an experimental combination therapy of two targeted small molecule inhibitors developed for oncology. JAB-3312 is a highly selective, allosteric inhibitor of SHP2 (encoded by PTPN11), which modulates RTK/RAS/MAPK signaling and relieves immunosuppression in the tumor microenvironment. Osimertinib is an approved third-generation EGFR tyrosine kinase inhibitor that binds irreversibly to mutant forms of EGFR, including T790M, and is approved for certain non-small cell lung cancers (NSCLC). The combination is being evaluated preclinically and in early clinical studies as a therapeutic approach for EGFR-mutant NSCLC, particularly addressing acquired resistance to osimertinib. Preclinical evidence suggests this combination can overcome resistance to osimertinib by blocking feedback activation of the RTK/RAS/MAPK pathway and enhancing tumor growth inhibition in resistant cancer models[3].

Other names

sitneprotafib + osimertinib